Consumer groups look to improve adverse event reporting systems.
Vastag
Brian
B
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects; D003258:Consumer Behavior; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D017277:Drug Approval; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D009101:Multiple Myeloma / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced; D000077268:Pamidronate; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate